Prothena Corporation plc Share Price & Technical Analysis
PRTA · $9.83 (+4.46%)
Healthcare / Biotechnology
$9.83
+4.46%
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develop…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-11% return in May, -8% avg return in past 3 year May month.
-1% return in 2026, -41% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -8% | -1% | 7% | 13% | -11% | – | – | – | – | – | – | – | -1% |
| 25 | 1% | 14% | -22% | -25% | -50% | 33% | 13% | 21% | 20% | 10% | 0% | -13% | 2% |
| 24 | -21% | -4% | -11% | -18% | 1% | -3% | 14% | -5% | -25% | 2% | -5% | -16% | -90% |
| 23 | -7% | -1% | -13% | 9% | 26% | 3% | 2% | -23% | -10% | -24% | -9% | 12% | -35% |
| 22 | -32% | 1% | 7% | -20% | -6% | -1% | 14% | -10% | 123% | 1% | 0% | -4% | 73% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$490.03M
P/E ratio
—
52W high
$11.80
52W low
$4.32
Volume
5,10,853
Beta
-0.23
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Prothena Corporation plc share price today?
- Prothena Corporation plc (PRTA) last traded around $9.83 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PRTA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PRTA. Download the app for real-time alerts.
- How can I analyze Prothena Corporation plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.